In this study, aflatoxin B1 (AFB1) aptamers were covalently coupled on the surface of magnetic beads to prepare aptamer affinity magnetic beads (AAMBs).Furthermore, the AAMBs, incubation solution, washing solution and eluate were pre-encapsulated in reagent strips to develop a single sample pretreatment kit of AFB1.The automatic pretreatment of AFB
Differential diagnoses in 83 dogs with icterus
ABSTRACT: Icterus (jaundice) is a yellowish pigmentation resulting from the depositing of bilirubin in tissues due to its high plasmatic concentration.The pathogenesis of icterus includes metabolic changes or obstructed bilirubin excretion and it is classified as pre-hepatic, hepatic and post-hepatic.This study aimed to evaluate and classify differ
Modelling of Reliability Indicators of a Mining Plant
The evaluation and prediction of reliability and testability of mining machinery and equipment are crucial, as advancements in mining technology have increased the importance of ensuring the safety of both the technological process and human life.This study focuses on developing a reliability model Service Power Set to analyze the controllability o
Pitfalls of relying on genetic testing only to diagnose inherited metabolic disorders in non-western populations - 5 cases of pyruvate dehydrogenase deficiency from South Africa
Pyruvate dehydrogenase complex (PDHC) deficiencies are a group of mainly infantile onset disorders stemming from defects in pyruvate catabolism.They are characterised by severe lactic acidosis and progressive neurodegeneration.Although the PDHA1 gene is implicated in most cases of PDHC deficiency worldwide, no pathogenic variants have been reported
Comparison of the effects of 3 different anti-VEGF drugs on cornea thickness, lens thickness and anterior chamber depth
To compare the long-term effects of 3 different anti-VEGF molecules on the lens, cornea and anterior chamber in phakic patients who have received Happy consecutive intravitreal injections.157 patients who did not have corneal pathology but were treated with 1.25mg/0.05ml intravitreal bevacizumab, 0.5mg/0.5ml ranibizumab or 2mg/0.05ml aflibercept in